Talaris Therapeutics Inc Stock
Talaris Therapeutics Inc Stock price
Key metrics
| Market capitalization | $637.19m |
| Enterprise Value | $347.99m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 1.88 |
| Dividend yield | 0.00% |
| Last dividend (FY23) | $15.12 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-63.76m |
Is Talaris Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
Talaris Therapeutics Inc Stock Analysis
Analyst Opinions
6 Analysts have issued a Talaris Therapeutics Inc forecast:
Analyst Opinions
6 Analysts have issued a Talaris Therapeutics Inc forecast:
Financial data from Talaris Therapeutics Inc
| Jun '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -65 -65 |
4%
4%
|
EBIT (Operating Income) EBIT | -64 -64 |
8%
8%
|
| Net Profit | -51 -51 |
32%
32%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Talaris Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Talaris Therapeutics Inc Stock News
Company Profile
Talaris Therapeutics, Inc. engages in cell therapy. It develops methods of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Its technologies are used to treat inherited metabolic enzyme disorders, red blood cell disorders to induce tolerance to organ transplants, and to treat autoimmune disorders such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and scleroderma. The company was founded by Suzanne Ildstad in 2002 and is headquartered in Louisville, KY.
| Head office | United States |
| CEO | Sandeep Kulkarni |
| Employees | 52 |
| Founded | 2021 |
| Website | www.tourmalinebio.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
